Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Travis Partin

Optometrist Tulsa, OK Doctor of Optometry

NPI 1982181855 CMS profile 5666858

10010 E 81St St, Tulsa, OK 74133

Open in the dashboard

General payments

$5,691

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Travis Partin of Tulsa, OK is reported in the CMS Open Payments database as having received $5,691 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $407 20
2024 General $200 9
2023 General $256 12
2022 General $860 35
2021 General $2,657 45
2020 General $504 12
2019 General $807 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Partin
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Travis Partin were reported at $407. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Travis Partin Optometrist median Middle half National median
2019 $807 $159 $67–$371 $163
2020 $504 $72 $29–$165 $114
2021 $2,657 $125 $46–$292 $132
2022 $860 $162 $66–$374 $149
2023 $256 $177 $72–$406 $160
2024 $200 $188 $77–$427 $164
2025 $407 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eyevance Pharmaceuticals LLC $1,596 7 payments
  2. Alcon Vision LLC $1,093 73 payments
  3. Allergan Inc. $505 6 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $260 7 payments
  5. Johnson & Johnson Vision Care, Inc. $258 7 payments
  6. Oyster Point Pharma, Inc. $185 4 payments
  7. Dompe US, Inc. $175 4 payments
  8. Kala Pharmaceuticals, Inc. $175 6 payments
  9. Optos, Inc. $157 4 payments
  10. AbbVie, Inc. $156 8 payments
  11. Other $1,132 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,461 150 payments
  2. Honoraria $1,200 1 payment
  3. Consulting Fee $30 1 payment
Products named General payments · program years 2019–2025
  1. Zerviate $1,465 3 payments
  2. DAILIES $332 44 payments
  3. Precision 1 $281 9 payments
  4. RESTASIS $253 3 payments
  5. PANOPTIX $252 2 payments
  6. Acuvue $205 5 payments
  7. OXERVATE $175 4 payments
  8. EYSUVIS $175 6 payments
  9. TYRVAYA $168 3 payments
  10. VYZULTA $160 7 payments
  11. Other $4,621 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

313

Median for Optometry: 120

Drug cost

$89,379

Median for Optometry: $8,864

Branded share of claims

51.8%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 25 $23,362
Miebo Perfluorohexyloctane/Pf Brand 29 $23,054
Xdemvy Lotilaner Brand 12 $22,747
Lumigan Bimatoprost Brand 18 $10,149
Simbrinza Brinzolamide/Brimonidine Tart Brand 15 $3,139
Prednisolone Acetate Generic 64 $1,860
Brimonidine Tartrate Generic 13 $1,580
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 32 $1,472
Moxifloxacin Moxifloxacin Hcl Brand 17 $654
Latanoprost Generic 35 $463

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$79,096

Medicare's payments for the services billed

Medicare patients

467

Average age 74

Services billed

1,029

271 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 50%
Ischemic heart disease 32%
Diabetes 28%
Chronic kidney disease 19%
Atrial fibrillation 16%
COPD 16%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record